Cargando…
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials
BACKGROUND: Patient selection is key in Phase I studies, and prognosis can be difficult to estimate in heavily pre-treated patients. Previous prognostic models like the Royal Marsden Hospital (RMH) score or using the neutrophil–lymphocyte ratio (NLR) have not been validated in current novel therapie...
Autores principales: | Loh, Jerold, Wu, Jiaxuan, Chieng, Jenny, Chan, Aurora, Yong, Wei-Peng, Sundar, Raghav, Lee, Soo-Chin, Wong, Andrea, Lim, Joline S. J., Tan, David S. P., Soo, Ross, Goh, Boon-Cher, Tai, Bee-Choo, Chee, Cheng E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070409/ https://www.ncbi.nlm.nih.gov/pubmed/36797357 http://dx.doi.org/10.1038/s41416-023-02193-2 |
Ejemplares similares
-
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020) -
Phase Ib Dose-Finding Study of Varlitinib Combined with Weekly Paclitaxel With or Without Carboplatin ± Trastuzumab in Advanced Solid Tumors
por: Lee, Matilda Xinwei, et al.
Publicado: (2022) -
Genotype-guided versus traditional clinical dosing of warfarin in patients of Asian ancestry: a randomized controlled trial
por: Syn, Nicholas L., et al.
Publicado: (2018) -
A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies
por: Chee, Cheng E., et al.
Publicado: (2023) -
A meta-analysis on immune checkpoint inhibitor efficacy for advanced non-small cell lung cancer between East Asians versus non-East Asians
por: Peng, Siyu, et al.
Publicado: (2020)